title: Atrial fibrillation: diagnosis and treatment.
abstract: Atrial fibrillation is the most common cardiac arrhythmia. It impairs cardiac function and increases the risk of stroke. The incidence of atrial fibrillation increases with age. Key treatment issues include deciding when to restore normal sinus rhythm, when to control rate only, and how to prevent thromboembolism. Rate control is the preferred management option in most patients. Rhythm control is an option for patients in whom rate control cannot be achieved or who have persistent symptoms despite rate control. The current recommendation for strict rate control is a resting heart rate of less than 80 beats per minute. However, one study has shown that more lenient rate control of less than 110 beats per minute while at rest was not inferior to strict rate control in preventing cardiac death, heart failure, stroke, and life-threatening arrhythmias. Anticoagulation therapy is needed with rate control and rhythm control to prevent stroke. Warfarin is superior to aspirin and clopidogrel in preventing stroke despite its narrow therapeutic range and increased risk of bleeding. Tools that predict the risk of stroke (e.g., CHADS2) and the risk of bleeding (e.g., Outpatient Bleeding Risk Index) are helpful in making decisions about anticoagulation therapy. Surgical options for atrial fibrillation include disruption of abnormal conduction pathways in the atria, and obliteration of the left atrial appendage. Catheter ablation is an option for restoring normal sinus rhythm in patients with paroxysmal atrial fibrillation and normal left atrial size. Referral to a cardiologist is warranted in patients who have complex cardiac disease; who are symptomatic on or unable to tolerate pharmacologic rate control; or who may be candidates for ablation or surgical interventions.
authors: University of California, San Diego, La Jolla, California 92093, USA. cagutierrez@ucsd.edu
authors: Cecilia
authors: C
authors: Gutierrez
authors: Daniel G
authors: DG
authors: Blanchard
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000145:classification / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D001772:Blood Cell Count; D006348:Cardiac Surgical Procedures; D017115:Catheter Ablation; D004452:Echocardiography; D004562:Electrocardiography; D006325:Heart Atria / Q000503:physiopathology; D006801:Humans; D010808:Physical Examination; D013902:Radiography, Thoracic; D012017:Referral and Consultation; D020521:Stroke / Q000517:prevention & control; D013972:Thyrotropin / Q000097:blood
chemical_list: D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D013972:Thyrotropin